UPM-Kymmene Oyj UPM.HE
Composite 50/100; the shares have moved about 23% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 32/100 — a moderate mark against it.
Growth ranks 68/100 — a moderate point in its favour. Income ranks 61/100 — a slight point in its favour. Balance-sheet strength ranks 58/100 — a slight point in its favour.
Quality ranks 32/100 — a moderate mark against it. Momentum ranks 36/100 — a moderate mark against it.
What the company does UPM-Kymmene is a global forest-based bioindustry company with seven segments spanning pulp, timber, energy, plywood, biochemicals, and specialty materials. Its diversified portfolio targets packaging, construction, healthcare, and transport end-markets.
Key financials UPM posts thin profitability with ROE 6% and ROA 3%, while gross and net margins are 12% and 7%. Revenue growth is flat at 1%, but EPS surged 124% on cost actions. Debt/equity is 0.38 and interest coverage 9.6x, indicating moderate leverage.
Stock health Quality scores are weak (35/100), but valuation (58/100) and income (64/100) are fair-to-attractive. Momentum is soft (39/100) with a 5% 3-month decline and RSI near neutral at 49. Dividend yield is 6.5% with a 127% payout ratio.
Price vs fair value The stock trades at a discount of 24.10% to our fair-value estimate of 28.92 and a discount of 6.82% to the 12-month target of 24.90. - Forward P/E of 12.09 vs trailing 19.75 (Valuation 57.5/100) - PEG of 0.19 signals deep undervaluation relative to growth (Growth 50.0/100) - Dividend yield 6.5% supports income appeal (Income 63.9/100) - Flat revenue growth 0.6% and weak quality scores (35.4/100) temper enthusiasm
Looking forward Analysts expect a re-rating as earnings normalize and markets stabilize. Execution on specialty-paper and biochemical initiatives could close the valuation gap.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.